Evidence map›Paper›PMID 41072409›Full record

ArticleCell reports. Medicine2025

Super-adjuvant nanoparticles for platform cancer vaccination.

Griffin I Kane, Tiana E Naylor, Ellis F Lusi, Meghan L Brassil, Kim Wigglesworth, Ronnie W Dinnell, Miranda B Diaz-Infante, Leah M Whiteman, John Lukas, Megan Winkler and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Griffin I KaneDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Tiana E NaylorDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Ellis F LusiDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Meghan L BrassilDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Kim WigglesworthDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Ronnie W DinnellDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Miranda B Diaz-InfanteDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Leah M WhitemanDepartment of Biology, University of Massachusetts Amherst, Amherst, MA, USA.
John LukasDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Megan WinklerDepartment of Biology, University of Massachusetts Amherst, Amherst, MA, USA.
Rohini JoshDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Julia CerruttiDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA.
Haruka MoriDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Stefania GallucciDivision of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Katherine A FitzgeraldDivision of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Prabhani U AtukoraleDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA, USA; Division of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA; UMass Cancer Center, University of Massachusetts Chan Medical School, Worcester, MA, USA. Electronic address: patukorale@umass.edu.

Funding

Designing a targeted 'super adjuvant' nanoparticle platform for vaccinationR21EB034465 · NIBIB · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ATUKORALE, PRABHANI · 2023 to 2025
$637k
Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccinationK22CA262355 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ATUKORALE, PRABHANI · 2021 to 2023
$583k
NCI NIH HHS K22 CA262355NIBIB NIH HHS R21 EB034465
6 · The paper itself

Abstract

We report on the utility of a "super-adjuvant" nanoparticle (NP) system as a modular, customizable platform for next-generation cancer vaccination. Using nanomaterials engineering technology, we aim to harness not only the effective adjuvanticity of whole-pathogen vaccines, but also the safety of subunit vaccines. Our lipid-based NP platform co-encapsulates agonists of the stimulator of interferon genes (STING) and Toll-like receptor 4 (TLR4) pathways to promote synergistic production of type I interferons and other proinflammatory cytokines in innate antigen-presenting dendritic cells and macrophages. Compared to empty NPs and free agonists, dual-adjuvant NPs administered with antigenic peptides or tumor cell lysate promote increased antigen processing and presentation, drain efficiently to nearby lymph nodes, increase polyfunctional tumor-specific T and B cells, and improve tumor-free outcomes upon vaccination and subsequent challenge with multiple aggressive tumor cells.

Indexed as

Adjuvants, ImmunologicCancer VaccinesNanoparticlesNeoplasmsVaccinationAnimalsAntigen PresentationDendritic CellsFemaleHumansMacrophagesMiceMice, Inbred C57BLToll-Like Receptor 4Adjuvants, ImmunologicCancer VaccinesToll-Like Receptor 4cancer vaccinationdual-agonist nanoparticlesimmunoengineeringlipid-based nanomaterialsnovel adjuvantsplatform therapySTINGTLR4

Identifiers

PMID41072409
PMCPMC12629812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.